Trials / Terminated
TerminatedNCT01805908
Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)
Imaging With 111In-Pertuzumab to Predict Response to Trastuzumab in HER2 Positive Metastatic or Locally Advanced Breast Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Ontario Clinical Oncology Group (OCOG) · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The general objective of the study is to improve the care of women with Human Epidermal Growth Factor Receptor-2 (HER2) positive metastatic or locally advanced breast cancer by using a radio-labelled biomarker with whole body Single Photon Emission Computed Tomography (SPECT) imaging to predict who will respond to treatment with Trastuzumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 111In-Pertuzumab + SPECT-CT | 111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory. |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2013-03-06
- Last updated
- 2016-06-06
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01805908. Inclusion in this directory is not an endorsement.